Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cyclacel Pharmaceuti (CYCC)

Cyclacel Pharmaceuti (CYCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,493
  • Shares Outstanding, K 1,463
  • Annual Sales, $ 420 K
  • Annual Income, $ -22,560 K
  • 60-Month Beta 0.52
  • Price/Sales 4.84
  • Price/Cash Flow N/A
  • Price/Book 1.48
Trade CYCC with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.54
  • Number of Estimates 1
  • High Estimate -0.54
  • Low Estimate -0.54
  • Prior Year -7.35
  • Growth Rate Est. (year over year) +92.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9517 +9.80%
on 08/29/24
1.2800 -18.36%
on 08/20/24
-0.2250 (-17.72%)
since 08/16/24
3-Month
0.9517 +9.80%
on 08/29/24
2.0000 -47.75%
on 06/26/24
-0.4550 (-30.33%)
since 06/18/24
52-Week
0.9517 +9.80%
on 08/29/24
11.3430 -90.79%
on 10/19/23
-3.7775 (-78.33%)
since 09/18/23

Most Recent Stories

More News
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

 - Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 –          - Demonstrated...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas

- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined,...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –          -Cash Runway to Mid 2023- ...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 1.0450 (+2.45%)
CYCCP : 7.00 (-9.44%)
Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 1.0450 (+2.45%)

Business Summary

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside...

See More

Key Turning Points

3rd Resistance Point 1.1467
2nd Resistance Point 1.1083
1st Resistance Point 1.0767
Last Price 1.0450
1st Support Level 1.0067
2nd Support Level 0.9683
3rd Support Level 0.9367

See More

52-Week High 11.3430
Fibonacci 61.8% 7.3735
Fibonacci 50% 6.1474
Fibonacci 38.2% 4.9212
Last Price 1.0450
52-Week Low 0.9517

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar